Erratum: Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer (PLoS ONE (2013) 8:8 (e71093) DOI: 10.1371/journal.pone.0071093);Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Hao, Huifang ^a,h   Maeda, Yutaka ^b   Fukazawa, Takuya ^a   Yamatsuji, Tomoki ^a   Takaoka, Munenori ^a   Bao, Xiao Hong ^a,g   Matsuoka, Junji ^c   Okui, Tatsuo ^c   Shimo, Tsuyoshi ^c   Takigawa, Nagio ^a   Tomono, Yasuko ^d   Nakajima, Motowo ^e   Fink Baldauf, Iris M ^b   Nelson, Sandra ^f   Seibel, William ^f   Papoian, Ruben ^f   Whitsett, Jeffrey A ^b   Naomoto, Yoshio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c OKAYAMA UNIVERSITY   (Japan)

^d Shigei Medical Research Institute and Hospital   (Japan)

^e SBI Pharmaceuticals Co   (Japan)

^f UNIVERSITY OF CINCINNATI   (United States)

^g JINZHOU MEDICAL UNIVERSITY   (China)

^h INNER MONGOLIA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (4 FLUOROBENZYL)IMIDAZO [2,1 BETA][1,3]THIAZOL 6 YL] 2H CHROMEN 2 ONE; ANTINEOPLASTIC AGENT; GROWTH FACTOR; GROWTH FACTOR PTN; MIDKINE; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; KRAS GENE; LUNG ADENOCARCINOMA; LUNG FIBROBLAST; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; COUMARINS; CYTOKINES; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; NEOPLASMS, EXPERIMENTAL; NERVE GROWTH FACTORS; PHOSPHATIDYLINOSITOL 3-KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIAZOLES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881592608     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0307052     Document Type: Erratum

References (34)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
4. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363: 1734-1739.
5. Zakowski MF, Ladanyi M, Kris MG, (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355: 213-215.
6. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18: 378-381.
7. Heist RS, Sequist LV, Engelman JA, (2012) Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol 7: 924-933.
8. Perez-Moreno P, Brambilla E, Thomas R, Soria JC, (2012) Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 18: 2443-2451.
9. Ayoola A, Barochia A, Belani K, Belani CP, (2012) Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 30: 433-446.
10. Tomizawa M, Yu L, Wada A, Tamaoki T, Kadomatsu K, et al. (2003) A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter. Br J Cancer 89: 1086-1090.
11. Takei Y, Kadomatsu K, Itoh H, Sato W, Nakazawa K, et al. (2002) 5′-,3′-inverted thymidine- modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277: 23800-23806.
12. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, et al. (2003) Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 94: 628-632.
13. Miyauchi M, Yoshida Y, Tada Y, Narita M, Maeda T, et al. (2001) Expression of herpes simplex virus-thymidine kinase gene controlled by a promoter region of the midkine gene confers selective cytotoxicity to ganciclovir in human carcinoma cells. Int J Cancer 91: 723-727.
14. Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, et al. (2000) Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 83: 701-706.
15. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, et al. (1993) A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 53: 1281-1285.
16. Owada K, Sanjo N, Kobayashi T, Mizusawa H, Muramatsu H, et al. (1999) Midkine inhibits caspase-dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. J Neurochem 73: 2084-2092.
17. Muramatsu T, (2002) Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 132: 359-371.
18. Jin Z, Lahat G, Korchin B, Nguyen T, Zhu QS, et al. (2008) Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 14: 5033-5042.
19. Ezquerra L, Herradon G, Nguyen T, Silos-Santiago I, Deuel TF, (2005) Midkine, a newly discovered regulator of the renin-angiotensin pathway in mouse aorta: significance of the pleiotrophin/midkine developmental gene family in angiotensin II signaling. Biochem Biophys Res Commun 333: 636-643.
20. Matsui T, Ichihara-Tanaka K, Lan C, Muramatsu H, Kondou T, et al. (2010) Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds. Int Arch Med 3: 12.
21. Matsushita A, Tabata M, Ueoka H, Kiura K, Shibayama T, et al. (1999) Establishment of a drug sensitivity panel using human lung cancer cell lines. Acta Med Okayama 53: 67-75.
22. Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, et al. (1997) Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int J Cancer 73: 367-370.
23. Watanabe N, Takaoka M, Sakurama K, Tomono Y, Hatakeyama S, et al. (2008) Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Clin Cancer Res 14: 4631-4639.
24. Reidy KJ, Villegas G, Teichman J, Veron D, Shen W, et al. (2009) Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. Development 136: 3979-3989.
25. Jazirehi AR, Wenn PB, Damavand M, (2012) Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res 2: 178-191.
26. Kaneko R, Tsuji N, Asanuma K, Tanabe H, Kobayashi D, et al. (2007) Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer. J Biol Chem 282: 19273-19281.
27. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, et al. (2005) Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 11: 3102-3108.
28. Sumida A, Horiba M, Ishiguro H, Takenaka H, Ueda N, et al. (2010) Midkine gene transfer after myocardial infarction in rats prevents remodelling and ameliorates cardiac dysfunction. Cardiovasc Res 86: 113-121.
29. Zhang N, Deuel TF, (1999) Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr Opin Hematol 6: 44-50.
30. Raica M, Cimpean AM, Ribatti D, (2009) Angiogenesis in pre-malignant conditions. Eur J Cancer 45: 1924-1934.
31. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
32. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
33. Maruyama K, Muramatsu H, Ishiguro N, Muramatsu T, (2004) Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 50: 1420-1429.
34. Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, et al. (2000) Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 105: 489-495.